Carcinoma, Hepatocellular Clinical Trial
Official title:
Image-Guided Radiation Therapy (IGRT) Associated With Concurrent Capecitabine and Oxaliplatin in the Treatment of Locally Advanced or Inoperable Hepatocellular Carcinoma (HCC): A Phase I Study
This is a phase I study to evaluate the safety of concurrent chemoradiation combining radiotherapy (IGRT) with two cytotoxic agents, capecitabine and oxaliplatin in patients with advanced or inoperable hepatocellular carcinoma.
In this phase I study, patients with advanced or inoperable hepatocellular carcinoma, or those failed other strategies will be recruited. The primary tumor and nearby metastatic nodes will be irradiated with Image-Guided Radiation Therapy (IGRT) mostly with conventional fractions. During the course, oral capecitabine and intravenous oxaliplatin will be given concurrently. The maximum tolerated dose (MTD) for the two drugs will be determined during escalation according to the occurrence of dose limiting toxicities (DLT). ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03289533 -
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
|
Phase 1 | |
| Terminated |
NCT01141478 -
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
|
N/A | |
| Recruiting |
NCT05580835 -
PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma
|
N/A | |
| Active, not recruiting |
NCT05389527 -
Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04560751 -
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
|
||
| Withdrawn |
NCT02939807 -
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT01915602 -
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
| Completed |
NCT04970212 -
Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
|
||
| Completed |
NCT01897038 -
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
| Terminated |
NCT01337492 -
Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)
|
Phase 0 | |
| Completed |
NCT01003015 -
Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT01012011 -
Regulatory Post Marketing Surveillance Study on Nexavar®
|
N/A | |
| Terminated |
NCT01020812 -
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00559455 -
Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT00384800 -
A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
| Terminated |
NCT00582400 -
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
|
Phase 2 | |
| Completed |
NCT00056992 -
Testing of ADI-PEG in Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT02859324 -
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
|
Phase 1/Phase 2 | |
| Terminated |
NCT02439008 -
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
|
N/A | |
| Completed |
NCT01915589 -
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
|
Phase 2 |